DTIL PRECISION BIOSCIENCES INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357874 · Fiscal year ends 05/21
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6,353.0%
TTM net income YoY53.9%
TTM EPS YoY103.6%
Revenue 3-yr CAGR-4.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-80.3%
Net margin-85.6%
FCF margin-115.0%
EBITDA margin-77.8%
Returns
ROE-112.7%
ROA-36.0%
ROIC (approx.)—
Asset turnover0.42x
Leverage & solvency
Liabilities / assets57.0%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-28.56x
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio12.4%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $10.84M | $34.20M | $13,000 | $18,000 | $29,000 | $638,000 |
| R&D expense | $12.74M | $12.39M | $13.11M | $14.46M | $13.35M | $12.77M | $13.59M | $15.91M |
| SG&A expense | $7.68M | $6.77M | $6.80M | $7.23M | $7.33M | $9.13M | $8.55M | $9.58M |
| Operating income | -$20.43M | -$19.16M | -$9.07M | $12.51M | -$20.67M | -$21.88M | -$22.11M | -$24.85M |
| Interest expense | $307,000 | $300,000 | $311,000 | $348,000 | $362,000 | $358,000 | $354,000 | $392,000 |
| Net income | -$7.59M | -$32.65M | -$18.44M | $20.13M | -$21.77M | -$23.52M | -$20.57M | -$17.75M |
| EBITDA | -$20.21M | -$18.91M | -$8.78M | $12.85M | -$20.32M | -$21.50M | -$21.72M | -$24.39M |
| EPS (basic) | -0.28 | -1.26 | -0.75 | — | -1.84 | -2.13 | -2.21 | — |
| EPS (diluted) | -0.28 | -1.26 | -0.75 | — | -1.84 | -2.13 | -2.21 | — |
| Weighted avg. shares (diluted) | 27.43M | 25.86M | 24.63M | — | 11.82M | 11.05M | 9.29M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $81.70M | $86.08M | $99.37M | $110.82M | $44.87M | $62.24M | $77.22M | $108.47M |
| Short-term investments | $148,000 | $1.47M | $1.81M | $4.76M | $0 | $0 | — | $413,000 |
| Receivables | $0 | $0 | $4.00M | $0 | $4,000 | $0 | $4,000 | $229,000 |
| Current assets | $86.58M | $91.55M | $108.69M | $118.74M | $51.70M | $70.26M | $82.10M | $94.99M |
| PP&E, net | $779,000 | $964,000 | $1.18M | $1.43M | $2.03M | $2.36M | $2.72M | $3.09M |
| Intangibles | $1.06M | $1.09M | $1.13M | $1.17M | $985,000 | $605,000 | $607,000 | $622,000 |
| Total assets | $120.38M | $125.92M | $143.89M | $154.42M | $93.51M | $108.93M | $124.41M | $136.39M |
| Current liabilities | $8.27M | $7.14M | $7.75M | $8.91M | $15.00M | $13.57M | $12.39M | $14.98M |
| Total liabilities | $68.60M | $80.63M | $67.79M | $62.17M | $76.88M | $74.87M | $75.07M | $80.00M |
| Shareholders' equity | $51.77M | $45.29M | $76.10M | $92.25M | $16.63M | $34.05M | $49.34M | $56.39M |
| Shares outstanding | 27.89M | 26.43M | 25.81M | 24.09M | 12.08M | 11.64M | 10.55M | 8.20M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.13M | -$13.44M | -$11.94M | -$11.25M | -$15.27M | -$20.27M | -$19.05M | -$18.68M |
| Capital expenditure | $0 | $0 | $18,000 | $19,000 | $0 | $2,000 | $64,000 | $97,000 |
| Free cash flow | -$15.13M | -$13.44M | -$11.96M | -$11.27M | -$15.27M | -$20.27M | -$19.12M | -$18.78M |
| Investing cash flow | -$200,000 | $1,000 | -$114,000 | -$325,000 | $17,000 | -$12,000 | -$314,000 | -$97,000 |
| Financing cash flow | $10.96M | $0 | $745,000 | $77.52M | $1.66M | $5.30M | $10.69M | $5.92M |
| Depreciation & amortization | $222,000 | $253,000 | $299,000 | $345,000 | $350,000 | $378,000 | $395,000 | $454,000 |
| Stock-based compensation | $2.96M | $1.84M | $1.55M | $2.04M | $2.39M | $2.94M | $2.82M | $3.57M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.